Yi-Bin Chen, MD; Nelson J. Chao, MD, MBA; Hannah Choe, MD; and Sophie Paczesny, MD, PhD, review updates in the diagnosis and treatment of graft-vs-host disease.
EP. 1: Overview of Graft-vs-Host Disease (GVHD)
Nelson J. Chao, MD, MBA, and Yi-Bin Chen, MD, define common signs and symptoms of GVHD and share insight on approaching the diagnosis of disease.
EP. 2: Challenges in Early Detection of GvHD
Hannah Choe, MD; Nelson J. Chao, MD, MBA; and Sophie Paczesny, MD, PhD, comment on the importance of early detection of disease and the role of biomarker testing in GVHD.
EP. 3: Selecting GVHD Prophylaxis
Nelson J. Chao, MD, MBA, reviews current GVHD prophylaxis options and factors to consider when selecting one for a given patient.
EP. 4: ASH 2021 Updates for GVHD Prophylaxis
Sophie Paczesny, MD, PhD; Yi-Bin Chen, MD; and Hannah Choe, MD, review recent advances in GVHD prophylaxis as presented at the 2021 American Society of Hematology (ASH) Annual Meeting and Symposium.
EP. 5: Impact of GVHD on Patient Outcomes
Yi-Bin Chen, MD, and Nelson J. Chao, MD, MBA, comment on the changing landscape of GVHD and the effect on patient outcomes.
EP. 6: Goals of Therapy for Acute GVHD Treatment
Hannah Choe, MD, discusses triggers to initiate acute GVHD therapy and goals of treatment.
EP. 7: Evolution of Treatment for Acute GVHD
Sophie Paczesny, MD, PhD, provides insight on how strategies to treat acute GVHD have changed over time regarding outcomes and pathophysiology of disease.
EP. 8: Overview of Steroid-Refractory Acute GVHD
Nelson J. Chao, MD, MBA, and Hannah Choe, MD, define steroid-refractory acute GVHD and current treatment options for the disease.
EP. 9: Steroids for First-Line Treatment of Chronic GVHD
Yi-Bin Chen, MD, leads a discussion on the use of steroids as first-line treatment of chronic GVHD and when to switch therapy.
EP. 10: Steroid-Refractory Chronic GVHD: Management Strategies
Hannah Choe, MD; Sophie Paczesny, MD, PhD; and Nelson J. Chao, MD, MBA, review the use of current FDA approved therapies—ruxolitinib, ibrutinib, and belumosudil—for the treatment of steroid-refractory chronic GVHD.
EP. 11: Treatment Selection for Steroid-Refractory GVHD
Hannah Choe, MD, leads the discussion on clinical experiences using off-label regimens to treat steroid-refractory chronic GVHD, and the optimal sequencing of therapy.
EP. 12: Future of Steroid-Refractory Chronic GVHD Treatment
Drs Hannah Choe, Yi-Bin Chen, Nelson J. Chao, and Sophie Paczesny explore emerging treatment options in the pipeline for the treatment of steroid-refractory chronic GVHD.
EP. 13: Clinical Manifestations of Chronic GVHD
Drs Hannah Choe, Nelson J. Chao, Sophie Paczesny, and Yi-Bin Chen share their approach to treating patients with chronic GVHD who present initially with either scleroderma or bronchiolitis obliterans.
EP. 14: Supportive Care for Steroid-Refractory Chronic GVHD Treatment
Hannah Choe, MD, leads a review of the role of supportive care and a multidisciplinary team approach to care for the treatment of steroid-refractory chronic GVHD.
EP. 15: Unmet Needs in GVHD Management
Drs Sophie Paczesny, Hannah Choe, Nelson J. Chao, and Yi-Bin Chen share unmet needs in GVHD and advice for disease management.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC